Program
cabozantinib
Also written as “Cabozantinib”, “XL184” and “Cabozantinib tablets”.
Its studies are mostly in Neoplasms · Carcinoma, Renal Cell · Prostatic Neoplasms · Carcinoma, Hepatocellular · Glioblastoma, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Exelixis | 237 open or running | phase 4since Jul 8, 2013 | Sep 20, 2005 | May 31, 2030phase 3 · NCT07620574 |
| Bristol-Myers Squibb | 51 open or running | phase 3since May 3, 2017 | Nov 24, 2009 | Aug 25, 2029phase 2 · NCT03899155 |
| Ipsen | 20 open or running | phase 2since May 9, 2019 | May 9, 2019 | none ahead |
| Takeda | 20 open or running | phase 2since Nov 8, 2017 | Nov 8, 2017 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortium | 10 open or running | phase 2since Apr 23, 2018 | Apr 23, 2018 | none ahead |
Also a collaborator on its studies: Novartis, clovis-oncology-inc, Johnson & Johnson, Ono Pharmaceutical, roche-genentech and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Sep 20, 2005.
- May 3, 2017Phase 3 study in Carcinoma, Renal CellBristol-Myers Squibb · NCT03141177 · 701 enrolled · United States, Argentina, Australia and more
- May 23, 2017Phase 1 study in Carcinoma, Transitional CellExelixis · NCT03170960 · 914 enrolled · United States, Australia, Belgium and more
- Nov 8, 2017Takeda's first study: phase 2 study in Advanced Renal Cell CarcinomaNew to TakedaTakeda · NCT03339219 · 35 enrolled · Japan
- Apr 23, 2018Academic Thoracic Oncology Medical Investigators Consortium's first study: phase 2 study in Colorectal NeoplasmsNew to Academic Thoracic Oncology Medical Investigators ConsortiumAcademic Thoracic Oncology Medical Investigators Consortium · NCT03542877 · 44 enrolled · United States
- Jun 29, 2018Phase 2 study in Advanced Hepatocellular CarcinomaTakeda · NCT03586973 · 34 enrolled · Japan
- Sep 26, 2018Phase 3 study in Thyroid Cancer, PapillaryExelixis · NCT03690388 · 187 enrolled · United States, Argentina, Australia and more
- Nov 26, 2018Phase 3 study in Carcinoma, HepatocellularExelixis · NCT03755791 · 837 enrolled · United States, Argentina, Australia and more
- Apr 1, 2019Phase 2 study in NeoplasmsBristol-Myers Squibb · NCT03899155 · 1,500 planned · United States, Argentina, Australia and more
- May 2, 2019Phase 3 study in Carcinoma, Renal CellExelixis · NCT03937219 · 855 enrolled · United States, Argentina, Australia and more
- May 9, 2019Ipsen's first study: phase 2 study in Carcinoma, Renal CellNew to IpsenIpsen · NCT03945773 · 127 enrolled · Austria, France, Germany and more
- Nov 1, 2019Phase 2 study in CarcinomaBristol-Myers Squibb · NCT04151563 · United States, Argentina, Belgium and more
- Jun 22, 2020Phase 3 study in Prostatic NeoplasmsExelixis · NCT04446117 · 575 enrolled · United States, Argentina, Australia and more
- Mar 4, 2024Phase 2 study in OsteosarcomaIpsen · NCT06341712 · 10 enrolled · United States, Belgium, Canada and more
- May 27, 2026Phase 3 study in NeoplasmsExelixis · NCT07620574 · 5,000 planned · United States
Ahead
- Aug 25, 2029Primary completion: phase 2 study in NeoplasmsBristol-Myers Squibb · NCT03899155
- May 31, 2030Primary completion: phase 3 study in NeoplasmsExelixis · NCT07620574
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zanzalintinibrule | Exelixis | phase 3 | 17 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07620574Neoplasms · United States | 3 | By invitation | Exelixis | May 31, 2030 | 5,000 |
| NCT06341712Osteosarcoma · United States, Belgium, Canada and more | 2 | Terminated | Ipsen | Feb 27, 2026 | 10 |
| NCT04446117Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Apr 19, 2024 | 575 |
| NCT04151563Carcinoma · United States, Argentina, Belgium and more | 2 | Withdrawn | Bristol-Myers Squibb | Dec 17, 2023 | 0 |
| NCT03945773Carcinoma, Renal Cell · Austria, France, Germany and more | 2 | Completed | Ipsen | May 11, 2023 | 127 |
| NCT03937219Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Jan 31, 2022 | 855 |
| NCT03899155Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Bristol-Myers Squibb | Aug 25, 2029 | 1,500 |
| NCT03755791Carcinoma, Hepatocellular · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Nov 30, 2021 | 837 |
| NCT03690388Thyroid Cancer, Papillary · United States, Argentina, Australia and more | 3 | Active, not recruiting | Exelixis | Aug 19, 2020 | 187 |
| NCT03586973Advanced Hepatocellular Carcinoma · Japan | 2 | Completed | Takeda | Jul 17, 2019 | 34 |
| NCT03542877Colorectal Neoplasms · United States | 2 | Completed | Academic Thoracic Oncology Medical Investigators Consortium | Oct 19, 2020 | 44 |
| NCT03339219Advanced Renal Cell Carcinoma · Japan | 2 | Completed | Takeda | Aug 25, 2020 | 35 |
| NCT03170960Carcinoma, Transitional Cell · United States, Australia, Belgium and more | 1 | Active, not recruiting | Exelixis | Feb 21, 2023 | 914 |
| NCT03141177Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Feb 12, 2020 | 701 |
| NCT01995058Prostatic Neoplasms · United States | 2 | Terminated | Exelixis | Nov 2014 | 54 |
| NCT01908426Carcinoma, Hepatocellular · United States, Australia, Belgium and more | 3 | Completed | Exelixis | Oct 16, 2017 | 707 |
| NCT01896479Carcinoma, Medullary · Australia, Canada, Croatia and more | 4 | Active, not recruiting | Exelixis | Jul 15, 2020 | 247 |
| NCT01865747Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Completed | Exelixis | May 22, 2015 | 658 |
| NCT01761773Renal Insufficiency · United States | 1 | Completed | Exelixis | Apr 2013 | 32 |
| NCT01658878Carcinoma, Hepatocellular · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Nov 12, 2024 | 657 |
| NCT01605227Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Exelixis | Sep 2014 | 1,028 |
| NCT01553656Neoplasms · Japan | 1 | Completed | Exelixis | May 2015 | 85 |
| NCT01522443Prostatic Neoplasms · United States, Australia, Canada and more | 3 | Terminated | Exelixis | Oct 2014 | 119 |
| NCT01493869Healthy · United States | 1 | Completed | Exelixis | May 2014 | 26 |
| NCT01100619Thyroid Cancer, Papillary · United States | 1 | Completed | Exelixis | Aug 2012 | 40 |
| NCT01068782Glioblastoma · United States, Canada | 2 | Terminated | Exelixis | May 2011 | 19 |
| NCT01018745Neoplasms · Japan | 1 | Completed | Bristol-Myers Squibb | Jul 2010 | 3 |
| NCT00960492Glioblastoma · United States | 1 | Completed | Exelixis | Nov 2012 | 26 |
| NCT00940225Neoplasms · United States, Belgium, Israel and more | 2 | Completed | Exelixis | May 2013 | 730 |
| NCT00704730Thyroid Neoplasms · United States, Austria, Belgium and more | 3 | Completed | Exelixis | Oct 2011 | 330 |
| NCT00704288Glioblastoma · United States | 2 | Completed | Exelixis | Jun 2012 | 222 |
| NCT00596648Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Exelixis | Aug 2, 2012 | 92 |
| NCT00215605Lymphoma · United States | 1 | Completed | Exelixis | Apr 2011 | 85 |
How it is read
Names in the registry
- “Cabozantinib”, 18 entries
- “cabozantinib”, 9 entries
- “XL184”, 6 entries
- “Cabozantinib tablets”, 2 entries
- “Cabozantinib (XL184) 140 mg”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 6 studies
- Carcinoma, Renal Cell, 5 studies
- Prostatic Neoplasms, 4 studies
- Carcinoma, Hepatocellular, 4 studies
- Glioblastoma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.